Literature DB >> 9360944

Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9).

B C Patterson1, Q A Sang.   

Abstract

Angiostatin is one of the most potent inhibitors of angiogenesis. Reports have shown that metalloelastase, pancreas elastase, plasmin reductase, and plasmin convert plasminogen to angiostatin. However, the cleavage sites of plasminogen by those enzymes have not been determined. Here we demonstrate that two members of the human matrix metalloproteinase (MMP) family, matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9), hydrolyze human plasminogen to generate angiostatin fragments. The cleavage sites have been determined. The 58-kDa bands derived from plasminogen by MMP-7 and MMP-9 both have the N-terminal sequence KVYLSEXKTG, which corresponds to that of angiostatin. This N terminus is identical to that of the starting plasminogen itself and corresponds to residues 97-106 of prepro-plasminogen. The 42- and 38-kDa bands generated by MMP-7 both have the N-terminal sequence VVLLPNVETP, which corresponds to the amino acid sequence 467-476 of prepro-plasminogen, between kringle domain 4 and 5. MMP-9 cleaves plasminogen to generate a 42-kDa fragment with the N-terminal sequence PVVLLPNVE, 1 residue upstream of the MMP-7 cleavage site. These results indicate that MMP-7 and MMP-9 may regulate new blood vessel formation by cleaving plasminogen and generating angiostatin molecules.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360944     DOI: 10.1074/jbc.272.46.28823

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  74 in total

Review 1.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.

Authors:  W G Stetler-Stevenson
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

Review 3.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

Review 4.  Proteases at the endometrial-trophoblast interface: their role in implantation.

Authors:  Lois A Salamonsen; Guiying Nie
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

Review 5.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

6.  Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.

Authors:  M S Stack; S Gately; L M Bafetti; J J Enghild; G A Soff
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

7.  Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

Authors:  Victor A Levin; Surasak Phuphanich; W K Alfred Yung; Peter A Forsyth; Rolando Del Maestro; James R Perry; Gregory N Fuller; Mark Baillet
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

Review 8.  Mathematical modeling of tumor-induced angiogenesis.

Authors:  Nikos V Mantzaris; Steve Webb; Hans G Othmer
Journal:  J Math Biol       Date:  2004-02-06       Impact factor: 2.259

9.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

10.  Macrophage fusion, giant cell formation, and the foreign body response require matrix metalloproteinase 9.

Authors:  Susan MacLauchlan; Eleni A Skokos; Norman Meznarich; Dana H Zhu; Sana Raoof; J Michael Shipley; Robert M Senior; Paul Bornstein; Themis R Kyriakides
Journal:  J Leukoc Biol       Date:  2009-01-13       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.